NEW YORK – CStone Pharmaceuticals said on Thursday that its new drug application of avapritinib (Ayvakit) for PDGFRA exon 18-mutated metastatic or unresectable gastrointestinal stromal tumors was accepted by China's National Medical Products Administration.